Larimar Therapeutics (LRMR)

• Market cap: $360M
• 1 day: -1.17%
• 5 days: -4.54%
• 1 month: 3.19%
• 3 months: 26.81%
• 6 months: 120.42%
• Year to date: 4.99%
• 1 year: -46.37%
• 5 years: -78.52%
• 10 years: -96.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Employees: 65